Zerofos contains Calcium acetate which helps patients with advanced renal insufficiency (creatinine clearance less than 30 mL/min) exhibit phosphate retention and some degree of hyperphosphatemia. The retention of phosphate plays a pivotal role in causing secondary hyperparathyroidism associated with osteodystrophy, and soft-tissue calcification. Calcium acetate (Zerofos) when taken with meals combines with dietary phosphate to form insoluble calcium phosphate which is excreted in the feces. Maintenance of serum phosphorus below 6.0 mg/dl is generally considered as a clinically acceptable outcome of treatment with phosphate binders.

Product Active Ingredient(s) Strength Features Dosage Form
ZEROFOS Calcium Acetate 667 mg • Control of hyperphosphatemia in end stage renal failure
• Does not promote aluminum absorption
• Dose not cause GI irritation
• Contains less elemental calcium
• Efficient methods to remove phosphate from dialysis patient
  • Zerofos is indicated for the control of hyperphosphatemia in end stage renal failure and does not promote aluminum absorption.


Copyright © 2013 - Alniche Life Sciences Pvt. Ltd. | All Rights Reserved

Disclaimer: The information provided herein is not medical advice and is not intended to replace medical advice offered by a health care provider. Please consult your health care provider for advice.